🍽️ nadolol,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Hypertension (High Blood Pressure): Nadolol is effective in lowering blood pressure levels by reducing the workload on the heart and relaxing blood vessels. By blocking the action of adrenaline (epinephrine) on the heart and blood vessels, nadolol helps to decrease the heart rate and dilate blood vessels, thereby lowering blood pressure. It is often prescribed as a first-line treatment for hypertension and may be used alone or in combination with other antihypertensive medications.

  2. Angina Pectoris: Nadolol may be used to prevent episodes of angina pectoris, a type of chest pain caused by reduced blood flow to the heart muscle. By reducing the heart rate and workload on the heart, nadolol helps to decrease oxygen demand by the heart, thereby preventing or reducing the severity and frequency of angina attacks.

  3. Arrhythmias: Nadolol is also indicated for the management of certain heart rhythm disorders, particularly supraventricular tachycardias (SVTs) such as atrial fibrillation and atrial flutter. By slowing down the heart rate and stabilizing the heart's electrical activity, nadolol can help to control abnormal heart rhythms and reduce the risk of complications associated with these conditions.

  4. Migraine Prophylaxis: In some cases, nadolol may be prescribed off-label for the prevention of migraine headaches. The exact mechanism by which nadolol exerts its migraine-preventive effects is not fully understood, but it is believed to involve its ability to reduce the excitability of neurons and alter the transmission of pain signals in the brain. Nadolol may help to reduce the frequency and severity of migraine attacks in certain individuals.

  5. Essential Tremor: Nadolol has been used off-label for the treatment of essential tremor, a neurological disorder characterized by involuntary shaking of the hands, arms, head, voice, or other parts of the body. Nadolol's beta-blocking properties may help to reduce tremor severity by stabilizing the activity of certain neurotransmitters in the brain.

  6. Portal Hypertension: Nadolol may also be used off-label in the management of portal hypertension, a condition characterized by high blood pressure in the portal vein system that carries blood from the digestive organs to the liver. By reducing portal vein pressure, nadolol can help to prevent complications such as variceal bleeding in individuals with cirrhosis or other liver diseases.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of nadolol,(prescription) On Probiotics

Rank Probiotic Impact
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by nadolol,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Ruminococcus genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Veillonella genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Bacteroides caccae species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Roseburia hominis species Decreases 📓 Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
[Ruminococcus] torques species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Bifidobacterium longum species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of nadolol,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.3 0.3
Acne 0 0
ADHD 0.7 0.2 2.5
Age-Related Macular Degeneration and Glaucoma 0.1 0.1
Allergic Rhinitis (Hay Fever) 0.1 0.2 -1
Allergies 0.5 0.8 -0.6
Allergy to milk products 0.5 0.1 4
Alopecia (Hair Loss) 0.1 0.1
Alzheimer's disease 0.9 1.7 -0.89
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.4 0.4 0
Ankylosing spondylitis 0.4 0.4 0
Anorexia Nervosa 0.5 -0.5
Antiphospholipid syndrome (APS) 0.1 0.3 -2
Asthma 0.1 0.1 0
Atherosclerosis 0.5 0.1 4
Atrial fibrillation 0.7 0.5 0.4
Autism 1.1 1.4 -0.27
Barrett esophagus cancer 0.1 0.1
benign prostatic hyperplasia 0 0
Bipolar Disorder 0.7 0.7 0
Brain Trauma 0.2 0.1 1
Cancer (General) 0.3 -0.3
Carcinoma 0.9 0.6 0.5
Celiac Disease 0.2 0.9 -3.5
Cerebral Palsy 0.1 0.5 -4
Chronic Fatigue Syndrome 1.6 1.4 0.14
Chronic Kidney Disease 0.2 0.4 -1
Chronic Lyme 0.1 -0.1
Chronic Obstructive Pulmonary Disease (COPD) 0.1 0.2 -1
Chronic Urticaria (Hives) 0.2 0.2 0
Coagulation / Micro clot triggering bacteria 0.1 0.4 -3
Colorectal Cancer 0.7 0.2 2.5
Constipation 0.1 0.1 0
Coronary artery disease 0.4 0.3 0.33
COVID-19 1.2 1.9 -0.58
Crohn's Disease 1.5 0.9 0.67
cystic fibrosis 0.1 0.2 -1
deep vein thrombosis 0.1 0.4 -3
Depression 1.1 1.5 -0.36
Dermatomyositis 0 0
Eczema 0.1 0.2 -1
Endometriosis 0.4 0.4 0
Eosinophilic Esophagitis 0.1 -0.1
Epilepsy 0.4 0.1 3
Fibromyalgia 0.1 0.5 -4
Functional constipation / chronic idiopathic constipation 0.8 0.7 0.14
gallstone disease (gsd) 0.5 0.1 4
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.2 0.2
Generalized anxiety disorder 0.1 0.3 -2
giant cell arteritis 0 0
Gout 0.2 -0.2
Graves' disease 0.2 0.2 0
Halitosis 0.2 0.2
Hashimoto's thyroiditis 0.2 0.4 -1
Hidradenitis Suppurativa 0.3 0.1 2
Histamine Issues 0.3 0 0
hypercholesterolemia (High Cholesterol) 0 0
hyperglycemia 0 0.1 0
Hyperlipidemia (High Blood Fats) 0.2 0.1 1
hypersomnia 0.3 -0.3
hypertension (High Blood Pressure 0.6 1 -0.67
Hypothyroidism 0.2 -0.2
Hypoxia 0.1 0.1
IgA nephropathy (IgAN) 0.2 -0.2
Inflammatory Bowel Disease 0.5 1.8 -2.6
Insomnia 0.1 0.1 0
Intelligence 0.2 0 0
Intracranial aneurysms 0.4 0.1 3
Irritable Bowel Syndrome 0.8 0.4 1
Liver Cirrhosis 1.1 1.1 0
Long COVID 0.9 2.1 -1.33
Low bone mineral density 0.2 -0.2
Lung Cancer 0.2 0.3 -0.5
Mast Cell Issues / mastitis 0 0.5 0
ME/CFS with IBS 0.1 0.4 -3
ME/CFS without IBS 0.2 0.1 1
Menopause 0.2 0.2
Metabolic Syndrome 1.8 1.4 0.29
Mood Disorders 2.3 1.6 0.44
multiple chemical sensitivity [MCS] 0.1 0.1
Multiple Sclerosis 0.8 0.6 0.33
Multiple system atrophy (MSA) 0.1 0.4 -3
neuropathic pain 0.2 -0.2
Neuropathy (all types) 0 0
neuropsychiatric disorders (PANDAS, PANS) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.2 0.7 -2.5
NonCeliac Gluten Sensitivity 0 0
Obesity 1.7 0.7 1.43
obsessive-compulsive disorder 1.1 0.4 1.75
Osteoarthritis 0.1 0.3 -2
Osteoporosis 0.6 0.1 5
Parkinson's Disease 0.7 0.8 -0.14
Polycystic ovary syndrome 0.4 0.7 -0.75
Postural orthostatic tachycardia syndrome 0 0.2 0
Premenstrual dysphoric disorder 0.2 0.2
primary biliary cholangitis 0.1 -0.1
Psoriasis 0.9 0.3 2
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.5 0.7 1.14
Rosacea 0.4 0.1 3
Schizophrenia 1.5 0.6 1.5
scoliosis 0.2 0.6 -2
Sjögren syndrome 0.4 0.2 1
Sleep Apnea 0.5 0.3 0.67
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0 0
Stress / posttraumatic stress disorder 0.2 0.5 -1.5
Systemic Lupus Erythematosus 0.9 0.4 1.25
Tic Disorder 0.3 0.2 0.5
Tourette syndrome 0.1 -0.1
Type 1 Diabetes 1.2 0.2 5
Type 2 Diabetes 1.8 0.9 1
Ulcerative colitis 0.2 0.8 -3
Unhealthy Ageing 0.9 0.3 2

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.222.64 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.64 ]